In addition, AI-assisted drug discovery yielded the identification of a small-molecule inhibitor of FASN, FASstatin, which boosted TRIM56-FASN interaction and increased TRIM56-driven FASN degradation and thus ameliorated NAFLD pathologies in mice with good efficacy, safety, and pharmacokinetics profiles. The gene discussed is FASN; the disease is metabolic dysfunction-associated steatotic liver disease.